Tyrosine phosphatase PTPRD suppresses colon cancer cell migration in coordination with CD44

Funato,Kosuke; Yamazumi,Yusuke; Oda,Takeaki; Akiyama,Tetsu

doi:10.3892/etm.2011.231

Tyrosine phosphatase PTPRD suppresses colon cancer cell migration in coordination with CD44

Authors:
- Kosuke Funato
- Yusuke Yamazumi
- Takeaki Oda
- Tetsu Akiyama
View Affiliations

Affiliations: Laboratory of Molecular and Genetic Information, Institute of Molecular and Cellular Biosciences, The University of Tokyo, Tokyo 113-0032, Japan
Published online on: March 21, 2011 https://doi.org/10.3892/etm.2011.231
Pages: 457-463

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

PTPRD is a receptor-type tyrosine-protein phosphatase. Recent analyses of comprehensive mutations and copy numbers have revealed that PTPRD is frequently mutated and homozygously deleted in various types of cancer, including glioblastoma, melanoma, breast and colon cancer. However, the molecular functions of PTPRD in cancer progression have yet to be elucidated. Herein, PTPRD suppressed colon cancer cell migration and was required for appropriate cell-cell adhesion. In addition, PTPRD regulated cell migration in cooperation with β-catenin/TCF signaling and its target CD44. Furthermore, expression levels of PTPRD were down-regulated in highly invasive cancers and were significantly correlated with patient survival. Our findings suggest that PTPRD is required for colon cancer invasion and progression.

View Figures

View References

1.	Tiganis T and Bennett A: Protein tyrosine phosphatase function: the substrate perspective. Biochem J. 402:1–15. 2007. View Article : Google Scholar : PubMed/NCBI
2.	Ensslen-Craig S and Brady-Kalnay S: Receptor protein tyrosine phosphatases regulate neural development and axon guidance. Dev Biol. 275:12–22. 2004. View Article : Google Scholar : PubMed/NCBI
3.	Stepanek L, Stoker A, Stoeckli E and Bixby J: Receptor tyrosine phosphatases guide vertebrate motor axons during development. J Neurosci. 25:3813–3823. 2005. View Article : Google Scholar : PubMed/NCBI
4.	Uetani N, Kato K, Ogura H, et al: Impaired learning with enhanced hippocampal long-term potentiation in PTPdeltadeficient mice. EMBO J. 19:2775–2785. 2000. View Article : Google Scholar : PubMed/NCBI
5.	Sjöblom T, Jones S, Wood L, et al: The consensus coding sequences of human breast and colorectal cancers. Science. 314:268–274. 2006.
6.	Weir B, Woo M, Getz G, et al: Characterizing the cancer genome in lung adenocarcinoma. Nature. 450:893–898. 2007. View Article : Google Scholar : PubMed/NCBI
7.	Network CGAR: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 455:1061–1068. 2008. View Article : Google Scholar : PubMed/NCBI
8.	Bignell G, Greenman C, Davies H, et al: Signatures of mutation and selection in the cancer genome. Nature. 463:893–898. 2010. View Article : Google Scholar : PubMed/NCBI
9.	Sato M, Takahashi K, Nagayama K, et al: Identification of chromosome arm 9p as the most frequent target of homozygous deletions in lung cancer. Genes Chromosomes Cancer. 44:405–414. 2005. View Article : Google Scholar : PubMed/NCBI
10.	Solomon D, Kim J, Cronin J, et al: Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Res. 68:10300–10306. 2008. View Article : Google Scholar : PubMed/NCBI
11.	Veeriah S, Brennan C, Meng S, et al: The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci USA. 106:9435–9440. 2009. View Article : Google Scholar
12.	Gonzalez-Brito M and Bixby J: Differential activities in adhesion and neurite growth of fibronectin type III repeats in the PTP-delta extracellular domain. Int J Dev Neurosci. 24:425–429. 2006. View Article : Google Scholar
13.	Serra-Pagès C, Medley Q, Tang M, Hart A and Streuli M: Liprins, a family of LAR transmembrane protein-tyrosine phosphataseinteracting proteins. J Biol Chem. 273:15611–15620. 1998.PubMed/NCBI
14.	Woodings J, Sharp S and Machesky L: MIM-B, a putative metastasis suppressor protein, binds to actin and to protein tyrosine phosphatase delta. Biochem J. 371:463–471. 2003. View Article : Google Scholar
15.	Gonzalez-Quevedo R, Shoffer M, Horng L and Oro A: Receptor tyrosine phosphatase-dependent cytoskeletal remodeling by the hedgehog-responsive gene MIM/BEG4. J Cell Biol. 168:453–463. 2005. View Article : Google Scholar : PubMed/NCBI
16.	Ponta H, Sherman L and Herrlich P: CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 4:33–45. 2003. View Article : Google Scholar : PubMed/NCBI
17.	Nakamura T, Hayashi T, Nasu-Nishimura Y, et al: PX-RICS mediates ER-to-Golgi transport of the N-cadherin/beta-catenin complex. Genes Dev. 22:1244–1256. 2008. View Article : Google Scholar : PubMed/NCBI
18.	Kawasaki Y, Sato R and Akiyama T: Mutated APC and Asef are involved in the migration of colorectal tumour cells. Nat Cell Biol. 5:211–215. 2003. View Article : Google Scholar : PubMed/NCBI
19.	Jeanes A, Gottardi C and Yap A: Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene. 27:6920–6929. 2008. View Article : Google Scholar : PubMed/NCBI
20.	Wang J and Bixby J: Receptor tyrosine phosphatase-delta is a homophilic, neurite-promoting cell adhesion molecular for CNS neurons. Mol Cell Neurosci. 14:370–384. 1999. View Article : Google Scholar : PubMed/NCBI
21.	Kawasaki Y, Sagara M, Shibata Y, Shirouzu M, Yokoyama S and Akiyama T: Identification and characterization of Asef2, a guanine-nucleotide exchange factor specific for Rac1 and Cdc42. Oncogene. 26:7620–7267. 2007. View Article : Google Scholar : PubMed/NCBI
22.	Gilles C, Polette M, Mestdagt M, et al: Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res. 63:2658–2664. 2003.PubMed/NCBI
23.	Gavert N, Conacci-Sorrell M, Gast D, et al: L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol. 168:633–642. 2005. View Article : Google Scholar : PubMed/NCBI
24.	Vignjevic D, Schoumacher M, Gavert N, et al: Fascin, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancer. Cancer Res. 67:6844–6853. 2007. View Article : Google Scholar : PubMed/NCBI
25.	Morin P, Sparks A, Korinek V, et al: Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 275:1787–1790. 1997. View Article : Google Scholar : PubMed/NCBI
26.	Sparks A, Morin P, Vogelstein B and Kinzler K: Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 58:1130–1134. 1998.PubMed/NCBI
27.	Fodde R and Brabletz T: Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol. 19:150–158. 2007. View Article : Google Scholar : PubMed/NCBI
28.	Wielenga V, Smits R, Korinek V, et al: Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol. 154:515–523. 1999. View Article : Google Scholar : PubMed/NCBI
29.	Boon E, van der Neut R, van de Wetering M, Clevers H and Pals S: Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res. 62:5126–5128. 2002.PubMed/NCBI
30.	Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S and Clarke M: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
31.	Du L, Wang H, He L, et al: CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res. 14:6751–6760. 2008. View Article : Google Scholar : PubMed/NCBI
32.	Van der Flier L, van Gijn M, Hatzis P, et al: Transcription factor achaete scute-like 2 controls intestinal stem cell fate. Cell. 136:903–912. 2009.PubMed/NCBI
33.	Zheng H, Ying H, Wiedemeyer R, et al: PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell. 17:497–509. 2010. View Article : Google Scholar : PubMed/NCBI
34.	O’Connell M and Weeraratna A: Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt. Pigment Cell Melanoma Res. 22:724–739. 2009.PubMed/NCBI
35.	Müller T, Choidas A, Reichmann E and Ullrich A: Phosphorylation and free pool of beta-catenin are regulated by tyrosine kinases and tyrosine phosphatases during epithelial cell migration. J Biol Chem. 274:10173–10183. 1999.PubMed/NCBI
36.	Siu R, Fladd C and Rotin D: N-cadherin is an in vivo substrate for protein tyrosine phosphatase sigma (PTPsigma) and participates in PTPsigma-mediated inhibition of axon growth. Mol Cell Biol. 27:208–219. 2007. View Article : Google Scholar : PubMed/NCBI
37.	Harder K, Moller N, Peacock J and Jirik F: Protein-tyrosine phosphatase alpha regulates Src family kinases and alters cellsubstratum adhesion. J Biol Chem. 273:31890–31900. 1998. View Article : Google Scholar : PubMed/NCBI
38.	Zhu S, Bjorge J and Fujita D: PTP1B contributes to the oncogenic properties of colon cancer cells through Src activation. Cancer Res. 67:10129–10137. 2007. View Article : Google Scholar : PubMed/NCBI